Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...
Shares of Moderna Inc. MRNA shed 6.86% to $46.83 Friday, on what proved to be an all-around favorable trading session for ...
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
Adam Glanzman / Bloomberg / Getty Images Moderna shares rose Thursday morning after reporting better results than expected for the third quarter. The vaccine maker reported a surprise profit and ...
Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin.
Let us delve deeper to understand whether to buy, sell, or hold Moderna stock at present. Year to date, Moderna’s shares have plunged 46.2% against the industry’s growth of 14.0%. The stock ...
Barchart on MSN2d
Moderna Stock Outlook: Is Wall Street Bullish or Bearish?Headquartered in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback